<DOC>
	<DOCNO>NCT00005627</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness estramustine , docetaxel , carboplatin treat patient prostate cancer respond hormonal therapy .</brief_summary>
	<brief_title>Estramustine , Docetaxel , Carboplatin Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose weekly docetaxel combine carboplatin estramustine patient hormone refractory prostate cancer . - Determine safety efficacy regimen patient population . OUTLINE : This dose escalation study docetaxel . Patients receive oral estramustine 3 time daily day 1-5 docetaxel IV 1 hour day 2 week 1-3 . Patients also receive carboplatin IV 1 hour day 2 week 1 . Treatment continue every 28 day 6 course absence unacceptable toxicity disease progression . Cohorts 3-5 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 5 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Disease progression follow androgen ablation therapy ( hormonal surgical ) either : Increase product bidimensional diameter 1 radiographically document site measurable disease OR Two consecutive increase PSA document previous reference value First increase PSA occur minimum 1 week reference value confirm First PSA value less previous value , patient eligible provide next PSA great second PSA Testosterone level document castrate range ( i.e. , less 30 ng/mL ) PATIENT CHARACTERISTICS : Age : 18 85 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT great 2.5 time upper limit normal ( ULN ) alkaline phosphatase normal OR Alkaline phosphatase great 4 time ULN SGOT normal OR SGOT great 1.5 time ULN alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past year No significant change anginal pattern within past 6 month No New York Heart Association class IIIV heart disease No deep venous thrombosis within past year Other : No significant peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow except taxanes platinum derivative Endocrine therapy : See Disease Characteristics At least 4 week since prior antiandrogens Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>